Atezolizumab pediatric population PK
A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
- Disease
- Pediatric and young-adult malignancies
Biological model
A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.
Model details
A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.
Modeled states
- AUC ug day mLug*day/mL
Modeled dynamic state for auc ug day ml.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
Key readouts
- Central atezolizumab concentrationunknown
Model-derived readout for central atezolizumab concentration.
- Cumulative atezolizumab exposureug*day/mL
Model-derived readout for cumulative atezolizumab exposure.
- Individual clearanceunknown
Model-derived readout for individual clearance.
- Individual central volumeunknown
Model-derived readout for individual central volume.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Child <30 kg, 15 mg/kg every 3 weeks dynamic scenario
How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?
CL ref L day
Model parameter controlling cl ref l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancerJournal for ImmunoTherapy of Cancer
